Online PARP Inhibitor Education Has Positive Impact on Oncologists’ and OB/GYNs’ Knowledge and Confidence
An online educational tool about PARP inhibitors improved clinicians’ confidence in their ability to use them correctly in women with newly diagnosed advanced ovarian cancer.
Establishing protocols for side-effect reporting and management beforehand can maximize adherence to PARP inhibitor maintenance therapy.
Although the combination of bevacizumab and olaparib showed superior progression-free survival compared with bevacizumab plus placebo as upfront maintenance therapy in women with advanced ovarian cancer, the lack of an olaparib monotherapy comparator limits meaningful interpretation.
No Difference in Overall Survival Between Nivolumab and Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer
The rate of overall survival was similar between nivolumab and either gemcitabine or pegylated liposomal doxorubicin in the open-label, randomized phase 3 NINJA clinical trial of patients with platinum-resistant ovarian cancer, but the overall duration of response was longer in the nivolumab arm.
Triplet Including Folate Receptor Alpha Antibody–Drug Conjugate Has Activity in Recurrent Ovarian Cancer
In the FORWARD II clinical trial, mirvetuximab soravtansine combined with carboplatin and bevacizumab induced an overall response rate of 83% in patients with recurrent platinum-sensitive ovarian cancer.
Copay Maximizer Programs Replacing Accumulator Programs with Ramifications for Patient Out-of-Pocket Expenses
Copay maximizer programs are replacing copay accumulator programs, and the trend toward increasing cost burden for patients continues.
Real-World Analysis Finds That Dabrafenib/Trametinib Combination Is Effective in Patients with BRAF V600-Mutated Melanoma with Brain Metastases
The combination of dabrafenib and trametinib performs as well in the real world as in clinical trials in patients with BRAF V600-mutated advanced melanoma and brain metastases, but the medical need for patients with brain metastases remains high.
Effectiveness of Dual Immunotherapy Confirmed for Patients with Metastatic Melanoma and Autoimmune Disease
The combination of ipilimumab and anti–PD-1 therapy showed efficacy comparable to clinical trial populations in patients with preexisting autoimmune disease and advanced melanoma.
Symptoms from Immunotherapy/Targeted Therapy Most Mentioned Topic by Patients with Melanoma on Health-Related Social Media
A review of posts to health-related social media over a 5-year period reveals that symptoms and their impact are the most frequently discussed topics by patients with melanoma and their caregivers.
Complete Responses Equally Durable with Shorter versus Longer Immunotherapy Courses in Advanced Melanoma
In a landmark single-institution analysis of patients with advanced melanoma, those who stopped their immunotherapy within 7 months of achieving a complete response had comparable disease-free survival to those who were treated for longer than 7 months.